Routine use of mebendazole in pregnancy.
BACKGROUND
The Ministry of Health has recommended the routine administration of a broad spectrum anthelmintic to all pregnant women after completion of the first trimester of pregnancy.


OBJECTIVE
To estimate prevalence and intensity of geohelminth infections in pregnant women attending an antenatal clinic in Ragama and determine the use of anthelmintics by them.


METHODS
Women on their first visit to antenatal clinics of the University Obstetrics Unit, General Hospital Colombo North, Ragama, during July-August 1995, were recruited for the study. Demographic details, duration of pregnancy and a history of using anthelmintics during the current pregnancy were noted. A stool sample was obtained and examined using modified Kato-Katz technique.


RESULTS
309 pregnant women were studied [mean age 26.6 years (SD 5.3)]. 94 (30.4%) had taken an anthelmintic during the current pregnancy. 78 (25.2%) had taken it in the second trimester, 9 (2.9%) in the third, 6 (1.8%) in the first, and one was uncertain of the timing. Stool samples were obtained from 181 women giving a compliance rate of 58.6%. Prevalence of geohelminth infections were: whipworm 10%, hookworm 2.2%, roundworm 1.1%. The intensities of the infections were mild. 157 (86.7%) did not have any geohelminth infection. Of the 181 women whose stools were examined, 52 had taken an anthelmintic. There was no significant difference in the prevalence of geohelminth infections between this group (6/52; 11.2%) and those who had not taken an anthelmintic (18/129; 13.9%) (Chi-square test).


CONCLUSIONS
It may not be necessary to treat all pregnant women in Sri Lanka with anthelmintics, as some areas have a low prevalence of infection. Routine anthelmintic therapy could-be limited to areas where prevalence rates are known to be high.
de Silva
N R
NR
Department of Parasitology, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka.
Kodituwakku
K K
KK
Edirisinghe
S S
SS
de Silva
H J
HJ
D000293:Adolescent; D000328:Adult; D000969:Antinematodal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003906:Developing Countries; D005260:Female; D006373:Helminthiasis / Q000517:prevention & control*; D006801:Humans; D008463:Mebendazole / Q000008:administration & dosage / Q000627:therapeutic use*; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000517:prevention & control*; D011262:Pregnancy Trimester, Second
D000969:Antinematodal Agents; D008463:Mebendazole